Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0GP8N
|
||||
| Former ID |
DNCL002353
|
||||
| Drug Name |
MK-8808
|
||||
| Indication | Late-stage follicular lymphoma [ICD9: 202.0, 202.8; ICD10:C81-C86, C82] | Phase 3 | [1] | ||
| Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 1 | [1] | |||
| Company |
Merck
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Agonist | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034367) | ||||
| REF 2 | Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.